Pemigatinib · Pemazyre
Small molecule
Evidence outlook
Approved: Cholangiocarcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signalSingle-arm, accepted for approval (FDA label)
Also in development:Non-Small Cell Lung Cancer · Phase 2
Also approved (4)
- Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
- Adults with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, previously treated
- Conditional marketing authorisation: locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one prior systemic therapy
- Unresectable biliary tract cancer with FGFR2 fusion gene, worsening after chemotherapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FIGHT-302 NCT03656536 · Cholangiocarcinoma FIGHT-302 was an open-label, randomized Phase 3 trial of first-line pemigatinib vs gemcitabine plus cisplatin in FGFR2-rearranged cholangiocarcinoma. It closed early after 167 patients because the first-line standard of care changed. The PFS primary favoured pemigatinib (8.3 vs 6.8 months, HR 0.58), but the paper reports the P value of .0078 as nominal, so the truncated trial gives no formal test of the primary. Response rates were higher (47% vs 15%) and overall survival was similar. The result cannot be classed as met or missed. Source: FIGHT-302 paper (PMID 42223137) and CT.gov posted results. Registry: NCT03656536 | 3 | Randomized Treatment Period: Progression-free Survival (PFS) (up to 1422 days); Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time (up to 1422 days); Transition Period: PFS (up to 1496 days); Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time (up to 1496 days) 2025-07-07 | PFS, pemigatinib vs gemcitabine-cisplatin: median 8.3 vs 6.8 months, hazard ratio 0.58 (95% CI 0.39 to 0.87), nominal P=.0078 (n=83 and 84); objective response 47% vs 15%; median OS 24.4 vs 25.0 months. Study closed early after a change in standard of care (J Clin Oncol paper, CT.gov posted results). | not yet graded | link ↗ |
View 1 more trial
FIGHT-202 NCT02924376 · Cholangiocarcinoma This was a non-randomized, open-label, single-arm study with no placebo or active comparator, so responses cannot be separated from the expected course of disease without treatment. The primary endpoint was a clinical tumor-response measure assessed by independent central imaging review, but there was no formal between-group comparison. Registry: NCT02924376 | 2 | Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions (up to 1527 days) 2022-02-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (40)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Cholangiocarcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pemigatinib (Pemazyre): this drug | Approved | Small molecule | FGFR1/2/3 | Weak signal | No reviewed efficacy summary in this indication | |
| Futibatinib (Lytgobi) | Approved | Small molecule | FGFR (FGFR1/2/3/4) | Weak signal | No reviewed efficacy summary in this indication | |
| Lirafugratinib (Lyrfigtu) | Approved | Small molecule | FGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| Tinengotinib | Phase 3 | Small molecule | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition) | Weak signal | Featured results are safety only in this race | |
| Toripalimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Pemazyre (Pemigatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.